Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...
Exhibit 10.1
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
AMENDMENT NO. AR5 TO
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT
This Amendment No. AR5 to the Amended and Restated Collaboration and License Agreement (the “Amendment No. AR5”), effective as of August 4, 2023 (the “Amendment No. AR5 Effective Date”), is by and between X. X. Xxxx Research, LLC, a Delaware limited liability company located at 000 Xxxx 00xx Xxxxxx, 00xx Xxxxx, Xxx Xxxx, XX 00000 (“DESRES”), and Relay Therapeutics, Inc., a Delaware corporation located at 000 Xxxxxx Xxxxxx, Xxxxxxxxx, XX 00000 (“Company”). DESRES and Company are each sometimes referred to herein as a “Party” or collectively as the “Parties”.
WHEREAS, DESRES and Company are parties to the Amended and Restated Collaboration and License Agreement, effective as of June 15, 2020, as amended by Amendment No. AR1 effective as of February 4, 2021, Amendment No. AR2 effective as of May 12, 2021, Amendment No. AR3 effective as of January 27, 2022, and Amendment No. AR4 effective as of March 22, 2023 (collectively, the “Agreement”);
WHEREAS, the Parties desire to clarify the categorization of certain Targets by mutual agreement, as set forth below;
NOW THEREFORE, the Parties agree, in accordance with Section 17.4 of the Agreement, as follows:
(d) Any [***] with which a targeted protein degrader that is designed to Interact with any Category 1 Target is also designed to Interact is and shall be deemed to be a Category 3 Target unless and until the Parties designate such [***] as a Category 1 Target or Category 2 Target in accordance with Section 4.7(e) of this Agreement.
1
[Signature Page Follows]
2
IN WITNESS WHEREOF, the Parties have caused this Amendment No. AR5 to be executed by their duly authorized representatives.
X. X. Xxxx Research, LLC |
|
By: /s/ Xxxxxxxx XxXxxxx |
By: /s/ Xxxxx Xxxxx |
Name: Xxxxxxxx XxXxxxx |
Name: Xxxxx Xxxxx |
Title: Authorized Signatory |
Title: Chief Legal Officer |
3